Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer
← catalyst calendarNCT04905069 · readout ≤ 499 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Prevention
Enrollment
500actual
Sites
30
Countries
Australia, France, Germany +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-12-21 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2021-05-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Prostate Cancer
Intervention
- Device: SpaceOAR Vue System
Primary outcome
what the primary-completion date above is the date OFLate Gastrointestinal (GI) Toxicity
measured 3 to 24 months post-SBRT initiation
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed